These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10354964)

  • 1. Feasibility and functionality of OROS melatonin in healthy subjects.
    Shah J; Langmuir V; Gupta SK
    J Clin Pharmacol; 1999 Jun; 39(6):606-12. PubMed ID: 10354964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults.
    Reiz JL; Donnelly GA; Michalko K
    Clin Ther; 2008 Jan; 30(1):59-69. PubMed ID: 18343243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline.
    Gupta SK; Shah JC; Hwang SS
    Br J Clin Pharmacol; 1999 Jul; 48(1):71-8. PubMed ID: 10383563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
    Gupta SK; Sathyan G
    J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melatonin potentiates testosterone-induced suppression of luteinizing hormone secretion in normal men.
    Anderson RA; Lincoln GA; Wu FC
    Hum Reprod; 1993 Nov; 8(11):1819-22. PubMed ID: 8288743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose proportionality and pharmacokinetics of extended-release (OROS®) hydromorphone: a phase 1, open-label, randomized, crossover study in healthy Taiwanese subjects.
    Vandenbossche J; Richards HM; Lu CC; Richarz U
    Int J Clin Pharmacol Ther; 2014 Mar; 52(3):217-26. PubMed ID: 24472398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed, middle-aged, and elderly patients.
    Siegrist C; Benedetti C; Orlando A; Beltrán JM; Tuchscherr L; Noseda CM; Brusco LI; Cardinali DP
    J Pineal Res; 2001 Jan; 30(1):34-42. PubMed ID: 11168905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age- and mental health-related circadian rhythms of plasma levels of melatonin, prolactin, luteinizing hormone and follicle-stimulating hormone in man.
    Touitou Y; Fèvre M; Lagoguey M; Carayon A; Bogdan A; Reinberg A; Beck H; Cesselin F; Touitou C
    J Endocrinol; 1981 Dec; 91(3):467-75. PubMed ID: 6799603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults.
    Gooneratne NS; Edwards AY; Zhou C; Cuellar N; Grandner MA; Barrett JS
    J Pineal Res; 2012 May; 52(4):437-45. PubMed ID: 22348451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation.
    Modi NB; Lindemulder B; Gupta SK
    J Clin Pharmacol; 2000 Apr; 40(4):379-88. PubMed ID: 10761165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized, Crossover, Pharmacokinetics Evaluation of a Novel Continuous Release and Absorption Melatonin Formulation.
    Seiden DJ; Shah SM
    Prim Care Companion CNS Disord; 2019 Aug; 21(4):. PubMed ID: 31381847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A melatonin preparation with a pulsatile liberation pattern: a new form of melatonin in replacement therapy.
    Hoffmann A; Farker K; Dittgen M; Hoffmann H
    Biol Signals Recept; 1999; 8(1-2):96-104. PubMed ID: 10085470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria.
    Shram MJ; Quinn AM; Chen N; Faulknor J; Luong D; Sellers EM; Endrenyi L
    Clin Ther; 2012 May; 34(5):1170-81. PubMed ID: 22512898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of an oral pulsatile delivery system for melatonin in humans.
    Hoffmann H; Dittgen M; Hoffmann A; Bartsch C; Breitbarth H; Timpe C; Farker K; Schmidt U; Mellinger U; Zimmermann H; Gräser T; Oettel M
    Pharmazie; 1998 Jul; 53(7):462-6. PubMed ID: 9699222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple-dose pharmacokinetics and pharmacodynamics of OROS and immediate-release amitriptyline hydrochloride formulations.
    Gupta SK; Shah J; Guinta D; Hwang S
    J Clin Pharmacol; 1998 Jan; 38(1):60-7. PubMed ID: 9597561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complex effects of melatonin on human circadian rhythms in constant dim light.
    Middleton B; Arendt J; Stone BM
    J Biol Rhythms; 1997 Oct; 12(5):467-77. PubMed ID: 9376645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma melatonin circadian rhythms during the menstrual cycle and after light therapy in premenstrual dysphoric disorder and normal control subjects.
    Parry BL; Berga SL; Mostofi N; Klauber MR; Resnick A
    J Biol Rhythms; 1997 Feb; 12(1):47-64. PubMed ID: 9104690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous melatonin levels and the fate of exogenous melatonin: age effects.
    Zhdanova IV; Wurtman RJ; Balcioglu A; Kartashov AI; Lynch HJ
    J Gerontol A Biol Sci Med Sci; 1998 Jul; 53(4):B293-8. PubMed ID: 18314560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bright light exposure and pituitary hormone secretion.
    Kostoglou-Athanassiou I; Treacher DF; Wheeler MJ; Forsling ML
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):73-9. PubMed ID: 9509071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.